P/E ratio for Global Cord Blood (CORBF)
P/E ratio as of July 2025 (TTM): 1.10
According to Global Cord Blood's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 1.10395. At the end of 2021 the company had a P/E ratio of 6.27.
P/E ratio history for Global Cord Blood from 2008 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 6.27 | -3% |
| 2020 | 6.47 | -29% |
| 2019 | 9.11 | -59.34% |
| 2018 | 22.4 | -23.26% |
| 2017 | 29.2 | -6.94% |
| 2016 | 31.4 | 0.71% |
| 2015 | 31.2 | 77.27% |
| 2014 | 17.6 | 4.54% |
| 2013 | 16.8 | |
| 2009 | 567 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Cryo-Cell CCEL | 16.0 | 1,349.89% | 🇺🇸 USA |
 NeoGenomics
NEO | -10.6 | -1,059.30% | 🇺🇸 USA |
 RadNet RDNT | -105 | -9,624.43% | 🇺🇸 USA |
 National Healthcare
NHC | 13.7 | 1,139.97% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.